Merck & Co. (MRK) To Present Data From APPROVe Trial At American College of Rheumatology Annual Scientific Meeting In San Antonio On Oct. 18
10/19/2005 5:11:49 PM
Merck & Co., Inc. today announced that it will present data from its APPROVe (Adenomatous Polyp Prevention on VIOXX) clinical trial at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Antonio on Oct. 18. The company announced a voluntary worldwide withdrawal of VIOXX(R) (rofecoxib), its arthritis and acute pain medication from the marketplace worldwide on Sept. 30, based on new, three-year data from the trial.
comments powered by